FibroBiologics raises ~$1.7M in registered direct offering at $0.33/share with warrants

FibroBiologics, Inc.

Sold 5,227,275 shares at $0.33/share; gross proceeds ~$1.7M; closing expected Dec 16, 2025.
Concurrent private placement of warrants to buy 5,227,275 shares at $0.33, exercisable only after stockholder approval, 5-year term.
CEO and prior purchaser entered voting agreements to support warrant share issuance under Nasdaq rules.
Placement agent H.C. Wainwright receives 7% cash fee and 365,909 warrants at $0.4125 per share.
Net proceeds for working capital and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.98

FibroBiologics, Inc. issued warrants to purchase up to 365,909 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC (placement agent) for services as placement agent.

Security: warrant
Shares: warrants to purchase up to 365,909 shares of Common Stock
Purchaser: H.C. Wainwright & Co., LLC (placement agent)
Consideration: services as placement agent

Exact text from the filing

the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 365,909 shares of Common Stock), at an exercise price of $0.4125 per share (the "Placement Agent Warrants").

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.98

FibroBiologics, Inc. issued 5,227,275 shares of Common Stock underlying Warrants of warrant to institutional investors for no additional consideration beyond the Purchase Agreement; exercise price $0.33 per share.

Security: warrant
Shares: 5,227,275 shares of Common Stock underlying Warrants
Purchaser: institutional investors
Consideration: no additional consideration beyond the Purchase Agreement; exercise price $0.33 per share

Exact text from the filing

5,227,275 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.33 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue to the Purchasers, in a concurrent private placement, warrants to purchase one

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.98

FibroBiologics, Inc. issued 5,227,275 shares of common stock to institutional investors for gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses.

Security: common stock
Shares: 5,227,275 shares
Purchaser: institutional investors
Consideration: gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses

Exact text from the filing

approval as described below. The exercise price of the Warrants is $0.33 per share. The gross proceeds to the Company from the offerings are expected to be approximately $1.7 million, before deducting placement agent fees and offering expenses payable by the Company. In addition, if the holders of the unregistered Warrants exercise such Warrants in full for

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.7 million (effective 2025-12-14).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $1.7 million
Effective: 2025-12-14

Exact text from the filing

On December 14, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 5,227,275 shares (the “Shares”) of the Company’s common stock

View on SEC.gov

43 equity issuances filed in the last 30 days. Browse all equity issuances →

FibroBiologics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-319441

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.